Pharma BD Deal Intelligence
A modest $8M all-stock merger that let HeartWare absorb WorldHeart's ventricular assist device assets. The deal delivered strong strategic fit but weak financial return, landing as a "Partially Achieved" outcome rather than a clear win.
HeartWare / WorldHeart: Partially Achieved (Score: 44/100)
Full analysis, sources & comparables →announced today that they have entered into a definitive merger agreement under which HeartWare will acquire WorldHeart for consideration of US$8 million, which will be paid in shares of HeartWare common stock or cash, at HeartWare s election.
HeartWare / WorldHeart: Partially Achieved (Score: 44/100)
Assessment window: 5yr post-close.
6.5M US cases/yr · $2.0B US LVAD/MCS Market (2012) · ~2,200 Heart Transplants/yr (US)
WorldHeart was a small LVAD developer. HeartWare acquired WorldHeart for $8M in stock, consolidating miniaturized LVAD IP. Advanced heart failure affects ~100,000 Americans with only ~2,200 transplants available.
HeartWare's HVAD was approved 2012. HeartWare was acquired by Medtronic (2016, $1.1B). HVAD was withdrawn 2021 due to safety issues. Abbott's HeartMate 3 became the dominant LVAD.
HeartWare closes acquisition/merger of WorldHeart for $8M, establishing strategic position and initiating integration.
Strategic Fit: 70/100 | Financial Return: 30/100 | Pipeline Outcome: 35/100 | Integration: 50/100 | Deal Difficulty: 50/100. Partially Achieved overall outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| HeartWare / WorldHeart (this deal) | 2012 | $8M | 48 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 2012 deals · Cardiovascular deals